The AI Biotech With 37,000 Virtual Employees Just Published in Science
Stanford's 37,000-agent Virtual Biotech mined 55,984 clinical trials and independently designed a lung cancer drug strategy Merck was already pursuing.
The First AI-Designed Drug Just Entered Phase III. Here's What That Actually Proves.
Insilico Medicine has pushed rentosertib, a drug whose target and molecule were both generated by AI, into a pivotal Phase III trial. It's the clearest test yet of whether AI drug discovery can produce medicines that work, not just headlines.